All News

lupus.jpg

Less Organ Damage with Remission in SLE

d Jack Cush, MD

A cohort study of SLE patients shows that remission and low disease activity (LDA) are associated with less damage accrual over time.

Read Article
lab.blood-315278__340.jpg

Utility of Repeat ENA Antibody Testing

d Jack Cush, MD

Repeat serologic testing is not uncommon, but is it warranted? A retrospective study shows that repeated testing for autoantibodies to extractable nuclear antigens (ENA) rarely changes the result or adds a new diagnosis. 

Read Article
Sleep.fatigue.doctor.jpg

Fatigue is Under-Appreciated in Psoriatic Arthritis

d Jack Cush, MD

Patient-reported fatigue is high in patients with psoriatic arthritis (PsA) and often goes under-recognized by physicians. Fatigue importantly impacts physical functioning, work productivity, and health related quality of life (HRQoL).

Read Article
GCA,Black

Increased Mortality in Giant Cell Arteritis

d Jack Cush, MD

A population-based study from Ontario, Canada suggests an increased mortality risk in patients with giant cell arteritis (GCA), according to a recent report in Arthritis Care & Research.

Read Article
monkey,pox

CDC Reviews Monkeypox

d MMWR

MMWR recently reviewed the epidemiology and characteristics of U.S. monkeypox cases seen between May and July 2022.

Read Article
URI.infection.COrona.jpg

More Bad Safety News for Xeljanz

d MedPage Today

Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.

Read Article
Should you do sural nerve biopsy (SNB) to Dx vasculitis? Study of 91 pts undergoing SNB suggests the SNB must be off sufficient length to improve Dx yield. 40/91 (44%) showed vasculitis. +SNB assoc w/ longer SNB sample, other organ Sxs & +ANCA https://t.co/aSC9xUfRFB https://t.co/lLRnrqXKaw

Links:

Dr. John Cush RheumNow ( View Tweet)
US national study of shows pregnancy in inflammatory bowel disease pts has higher risks for: - gestational diabetes (AOR) - HTN complications (1.35) - Pre-term births (1.41) - Fetal growth restriction (1.27) - Fetal death (3.21) https://t.co/3XTrrrNmoe https://t.co/udl7dXT5IF

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC Reviews Monkeypox - 99% men, 94% male-to-male sexual contact; less prodrome; rash (100% including genital), fever (63%), chills (59%), and lymphadenopathy (59%) https://t.co/OUQPXh0RQq https://t.co/GWpomlj5PX https://t.co/VC6mg35J1Q

Links:

Dr. John Cush RheumNow ( View Tweet)
150 PsA pts assessed preferences in chosing biologics (of most to less preferred): 1 Oral over SC or IV routes 2 Avoiding severe side effects 3 Resume normal activity 4 Avoid infections 5 Improve enthesitis & 6 psoriasis 7 remission 8 Joint pain https://t.co/kE3qtTWBhH https://t.co/KKcsQqEYKf

Links:

Dr. John Cush RheumNow ( View Tweet)
Awards issued by ACR, EULAR, BSR Reveal Gender Gap in last 2 decades. While # awards increased (including women), absolute %female prize winners remains lower than males (among 41 total awards). ACR: only ~20% recv top gold medal or Master awards https://t.co/lI548NmeW3 https://t.co/AfRwBANLOE

Links:

Dr. John Cush RheumNow ( View Tweet)
More Bad Safety News for Xeljanz Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in RA are higher than with TNF inhibitors. https://t.co/5FIwRMXdbT https://t.co/8k4NU6Rh6T

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA Registry study of Kids who D/C DMARDs or biologics but flared & restarted meds: the recapture rate was 55% overall (47% oligoarthritis, 69% systemic JIA. By 12 mos 67% of children achieved inactive dz - better odds w/ restarting biologics (OR 2.74) https://t.co/Psgtd0O2jO https://t.co/xsecVRJqOL

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 189 new non-infectious anterior uveitis pts, found a high prevalence SpA (56%), 93% w/ axial SpA, few (7) w/ peripheral SpA. 74/106 were newly Dx SpA. SpA predictors: psoriasis (OR 12.5), B27+ (OR 6.3),^CRP (OR 4.8) & male (OR 2.1) https://t.co/uTLmJ2QU1A https://t.co/2rejvp3yTa

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of diet & RA in 100 new RA & 197 controls; fish/seafood consumption assoc w/ less RA risk (OR 0.52; 0.27–0.98); but processed meat intake yielded increased RA risk (OR 3.45; CI 1.78–6.68). No significant association btw RA and red meats or poultry https://t.co/wLpHfA50mY https://t.co/p2EOLBKrwW

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors in Difficult Still’s Disease A small retrospective study suggests that patients with difficult to treat AOSD or sJIA may respond well to JAKi agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN. https://t.co/cH9wb8bPTX https://t.co/Xm7DUC5okk

Links:

Dr. John Cush RheumNow ( View Tweet)
Lilly has announced that Taltz (ixekizumab) is now available as a Citrate-Free Formulation to reduce injection site pain for patients with psoriasis, psoriatic arthritis, spondyloarthritis & nonradiographic axial spondyloarthritis. https://t.co/kFQVUdalQp https://t.co/UKtFzReIe6

Links:

Dr. John Cush RheumNow ( View Tweet)
Amgen and ChemoCentryx, (maker of newly approved Avacopan)have entered into a definitive agreement wherein Amgen will acquire ChemoCentryx for ~$3.7 billion ($52 per share). https://t.co/8quO9ET8vH https://t.co/AphPizgKo8

Links:

Dr. John Cush RheumNow ( View Tweet)
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/IoWISgL3SY https://t.co/JV1Yv5Pg9d https://t.co/b8UoQ4zMUV https://t.co/VwNgVQ5End

Links:

Dr. John Cush RheumNow ( View Tweet)
Evusheld works & reduces COVID-19 by 77%; yet only 25% of available Rx has been used. Its FREE to the ~7000 immunocompromised pts who might benefit from it. Repeat doses (300 mg) every 6 mos! Time to jump on this! https://t.co/IzcAUvKoW8 https://t.co/h5q25yWCHG

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×